CA2597485A1 - Methods and compositions for modulating tweak and fn14 activity - Google Patents

Methods and compositions for modulating tweak and fn14 activity Download PDF

Info

Publication number
CA2597485A1
CA2597485A1 CA002597485A CA2597485A CA2597485A1 CA 2597485 A1 CA2597485 A1 CA 2597485A1 CA 002597485 A CA002597485 A CA 002597485A CA 2597485 A CA2597485 A CA 2597485A CA 2597485 A1 CA2597485 A1 CA 2597485A1
Authority
CA
Canada
Prior art keywords
tweak
antibody
receptor
cells
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002597485A
Other languages
English (en)
French (fr)
Inventor
Avi J. Ashkenazi
Heather Maecker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36953868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2597485(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2597485A1 publication Critical patent/CA2597485A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002597485A 2005-03-07 2006-03-02 Methods and compositions for modulating tweak and fn14 activity Abandoned CA2597485A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65933905P 2005-03-07 2005-03-07
US60/659,339 2005-03-07
PCT/US2006/007547 WO2006096487A2 (en) 2005-03-07 2006-03-02 Methods and compositions for modulating tweak and fn14 activity

Publications (1)

Publication Number Publication Date
CA2597485A1 true CA2597485A1 (en) 2006-09-14

Family

ID=36953868

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002597485A Abandoned CA2597485A1 (en) 2005-03-07 2006-03-02 Methods and compositions for modulating tweak and fn14 activity

Country Status (12)

Country Link
US (2) US20080286271A1 (https=)
EP (1) EP1853312B1 (https=)
JP (2) JP2008531746A (https=)
KR (3) KR20130089271A (https=)
CN (2) CN101171035A (https=)
AU (1) AU2006220825A1 (https=)
BR (1) BRPI0608012A2 (https=)
CA (1) CA2597485A1 (https=)
IL (1) IL185180A0 (https=)
RU (1) RU2007137060A (https=)
WO (1) WO2006096487A2 (https=)
ZA (1) ZA200707489B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5550799B2 (ja) 1999-01-15 2014-07-16 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｔｗｅａｋのアンタゴニストおよびｔｗｅａｋレセプターのアンタゴニスト、ならびに免疫学的障害を処置するためのこれらの使用
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
EA011607B1 (ru) 2002-04-09 2009-04-28 Байоджен Айдек Ма Инк. Способ лечения заболеваний, связанных с tweak
EP2529619B1 (en) 2005-02-17 2015-09-23 Biogen MA Inc. Treating neurological disorders
US20090068102A1 (en) * 2005-02-17 2009-03-12 Biogen Idec Ma Inc. Treating stroke
WO2006096487A2 (en) * 2005-03-07 2006-09-14 Genentech, Inc. Methods and compositions for modulating tweak and fn14 activity
JP5339901B2 (ja) * 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
DK1888113T3 (da) * 2005-05-27 2014-09-01 Biogen Idec Inc Tweak-bindende antistoffer
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
WO2008048924A2 (en) * 2006-10-16 2008-04-24 Biogen Idec Ma Inc. Biomarkers of multiple sclerosis
WO2009020933A2 (en) * 2007-08-03 2009-02-12 Facet Biotech Corporation Therapeutic use of anti-tweak receptor antibodies
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US20120055055A1 (en) * 2010-09-02 2012-03-08 Illumin8 Outdoor Media, LLC Systems and Method for Outdoor Media Signage
KR101584416B1 (ko) * 2010-10-05 2016-01-13 에프. 호프만-라 로슈 아게 인간 tweak에 대한 항체 및 그의 용도
CA2827759C (en) 2011-03-10 2018-10-16 Omeros Corporation Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
CN105779576B (zh) * 2014-12-25 2025-01-17 中国人民解放军第四军医大学 人tnfrsf12a基因的用途及其相关药物
EP3548097A4 (en) 2016-12-02 2020-07-01 Avelas Biosciences, Inc. NERVE MARKING COMPOSITIONS AND USES THEREOF
MX2021004976A (es) * 2018-10-31 2021-06-15 Astellas Pharma Inc Anticuerpo fn14 antihumano.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001513626A (ja) * 1997-02-12 2001-09-04 アボツト・ラボラトリーズ 疾患の治療及び診断のために有用なｔｎｆファミリーのメンバー
JP5550799B2 (ja) * 1999-01-15 2014-07-16 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｔｗｅａｋのアンタゴニストおよびｔｗｅａｋレセプターのアンタゴニスト、ならびに免疫学的障害を処置するためのこれらの使用
ATE363489T1 (de) * 1999-03-08 2007-06-15 Genentech Inc In tumoren vervielfältigte gensequenzen und deren diagnostische verwendungen
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
US6727225B2 (en) * 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
EP1239869B1 (en) * 1999-12-20 2013-08-28 Immunex Corporation Tweak receptor
EP2260867A1 (en) * 2000-09-14 2010-12-15 Biogen Idec MA Inc. TWEAK receptor agonists as anti-angiogenic agents
CA2427858A1 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
CA2587018A1 (en) * 2004-11-08 2006-05-18 University Of Maryland, Baltimore Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
WO2006096487A2 (en) * 2005-03-07 2006-09-14 Genentech, Inc. Methods and compositions for modulating tweak and fn14 activity

Also Published As

Publication number Publication date
BRPI0608012A2 (pt) 2009-11-03
CN102225200A (zh) 2011-10-26
JP2008531746A (ja) 2008-08-14
CN101171035A (zh) 2008-04-30
EP1853312A2 (en) 2007-11-14
EP1853312B1 (en) 2014-12-10
WO2006096487A3 (en) 2007-09-13
IL185180A0 (en) 2008-12-29
KR20130089271A (ko) 2013-08-09
RU2007137060A (ru) 2009-04-20
ZA200707489B (en) 2008-12-31
WO2006096487A2 (en) 2006-09-14
AU2006220825A1 (en) 2006-09-14
AU2006220825A2 (en) 2006-09-14
KR20150031459A (ko) 2015-03-24
US20120269808A1 (en) 2012-10-25
US20080286271A1 (en) 2008-11-20
JP2014111605A (ja) 2014-06-19
KR20070108537A (ko) 2007-11-12

Similar Documents

Publication Publication Date Title
US20120269808A1 (en) Methods and compositions for modulating tweak and fn14 activity
AU2002366430B2 (en) Human DR4 antibodies and uses thereof
US20050043516A1 (en) TACI antibodies and uses thereof
CA2594918C (en) Dr5 antibodies and uses thereof
US20050070689A1 (en) Taci and br3 polypeptides and uses thereof
AU781952B2 (en) DR4 antibodies and uses thereof
JP2005517021A5 (https=)
AU2016238953A1 (en) Methods and compositions for modulating TWEAK and FN14 activity
AU2012211353A1 (en) Methods and compositions for modulating TWEAK and FN14 activity
AU2014268213A1 (en) Methods and compositions for modulating TWEAK and FN14 activity
MX2007010917A (es) Metodos y composiciones para modular la actividad de tweak y fn14
HK1065323B (en) Human dr4 antibodies and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20160411